Results 121 to 130 of about 60,617 (307)

ErbB4 Preserves Blood-Brain Barrier Integrity via the YAP/PIK3CB Pathway After Subarachnoid Hemorrhage in Rats

open access: yesFrontiers in Neuroscience, 2018
Studies have suggested that blood-brain barrier (BBB) disruption contributes to the pathogenesis of early brain injury after subarachnoid haemorrhage (SAH).
Huan Qian   +5 more
doaj   +1 more source

Single‐Cell Transcriptomics Reveals FLS2‐Dependent Hypoxia Signaling and ERF13‐Mediated Transcription During flg22‐Triggered Immunity

open access: yesAdvanced Science, EarlyView.
This study employs sc‐RNA sequencing, genetics, and phenotyping to systematically map the cell‐type‐specific immune responses triggered by flg22. It reveals FLS2‐dependent transcriptional reprogramming in epidermal and mesophyll cells, and uncovers crosstalk between immune and hypoxia signaling pathways.
Yaping Zhou   +17 more
wiley   +1 more source

YAP‐TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape

open access: yesFEBS Open Bio
Cholangiocarcinoma (CCA) is a highly aggressive form of liver cancer and is an increasing cause of cancer‐related death worldwide. Despite its increasing incidence globally and alarming mortality, treatment options for CCA have largely remained unchanged,
Roberto Alva‐Ruiz   +13 more
doaj   +1 more source

Sub-cellular localisation studies may spuriously detect the Yes-associated protein, YAP, in nucleoli leading to potentially invalid conclusions of its function.

open access: yesPLoS ONE, 2015
The Yes-associated protein (YAP) is a potent transcriptional co-activator that functions as a nuclear effector of the Hippo signaling pathway. YAP is oncogenic and its activity is linked to its cellular abundance and nuclear localisation.
Megan L Finch   +4 more
doaj   +1 more source

Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling [PDF]

open access: hybrid, 2019
Udhayakumar Gopal   +3 more
openalex   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode   +16 more
wiley   +1 more source

OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer [PDF]

open access: hybrid, 2022
Cheng Yan   +13 more
openalex   +1 more source

ECM‐Stiffness Mediated Persistent Fibroblast Activation Requires Integrin and Formin Dependent Chromatin Remodeling

open access: yesAdvanced Science, EarlyView.
Prolonged exposure to stiff extracellular matrix drives cancer‐associated fibroblasts into a persistently activated myofibroblast state. Two parallel pathways are identified: β1 integrin activation smoothens the nuclear lamina to reduce lamin–chromatin contacts, while the formin mDia2 regulates nuclear actin to alter chromatin organization.
Swathi Packirisamy   +4 more
wiley   +1 more source

Blockade of Crk eliminates Yki/YAP-activated tumors via JNK-mediated apoptosis in Drosophila

open access: yesCommunications Biology
Selective elimination of cancer cells without causing deleterious effects on normal cells is an ideal anti-cancer strategy. Here, using Drosophila cancer model, we performed an in vivo RNAi screen for anti-cancer targets that selectively eliminate tumors
Bungo Kakemura, Tatsushi Igaki
doaj   +1 more source

Home - About - Disclaimer - Privacy